Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill

Hypertension is a major, if not the most important, contributor to the disease burden and premature death globally which is largely related to cardiovascular disease. In both the primary and the secondary preventions of cardiovascular disease, blood pressure (BP) targets are often not achieved which...

Full description

Saved in:
Bibliographic Details
Published in:Current hypertension reports 2016-04, Vol.18 (5), p.40-40, Article 40
Main Authors: Lafeber, M., Spiering, W., Visseren, F. L. J., Grobbee, D. E.
Format: Article
Language:English
Subjects:
Antihypertensive Agents - therapeutic use
Blood Pressure - drug effects
Cardiology
Cardiovascular Diseases - complications
Cardiovascular Diseases - etiology
Cardiovascular Diseases - physiopathology
Cardiovascular Diseases - prevention & control
Family Medicine
General Practice
Humans
Hypertension - complications
Hypertension - drug therapy
Internal Medicine
Medicine
Medicine & Public Health
Metabolic Diseases
Nephrology
Novel Treatments for Hypertension (T Unger
Novel Treatments for Hypertension (T Unger, Section Editor)
Primary Care Medicine
Risk Factors
Section Editor
Topical Collection on Novel Treatments for Hypertension
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypertension is a major, if not the most important, contributor to the disease burden and premature death globally which is largely related to cardiovascular disease. In both the primary and the secondary preventions of cardiovascular disease, blood pressure (BP) targets are often not achieved which is similar to achievement of cholesterol goals. Combining aspirin, cholesterol and blood pressure-lowering agents into a fixed-dose combination pill called the cardiovascular polypill has been proposed as complementary care in the prevention of cardiovascular diseases in both the primary and secondary preventions of cardiovascular disease. This review article focuses on the potential role of fixed-dose combination therapy in the treatment of hypertension, outlines the pros and cons of combination therapy and emphasizes the rationale for trialling their use. Current and planned future cardiovascular polypill trials are summarized, and the prerequisites for implementation of the polypill strategy are described.
ISSN:1522-6417
1534-3111
DOI:10.1007/s11906-016-0648-3